Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
The purpose of this study is to demonstrate that a paliperidone palmitate 3 month formulation (PP3M) is as effective as the paliperidone palmitate 1 month formulation (PP1M) in the treatment of patients with schizophrenia who have been stabilized on PP1M.
Epistemonikos ID: d95515c972a00ad626d313d0b333dd5da81446f9
First added on: May 10, 2024